Janssen begins global collaboration with Theravance Biopharma for an oral inhibitor drug candidate Pan-JAK for the treatment of inflammatory bowel disease
[ad_1] HORSHAM, Pennsylvania., Feb. 7, 2018 / PRNewswire / – Pharmaceutical companies Janssen of Johnson & Johnson announced today that they have entered a global collaboration with a subsidiary of Theravance Biopharma, Inc. to develop TD-1473, an oral, gastrointestinal ( GI) restricted first class. -Janus kinase inhibitor (JAK) for the treatment of inflammatory bowel disease […]